Drugs / ALA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02632110 | Mar → Sep 2016 | actinic keratosis | DUSA Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02632110 ↗ |
| Route | Topical | “20% ALA applied to face prior to light treatment” NCT02632110 ↗ |